{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:19:48Z","timestamp":1791443988202,"version":"4.3.3"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13318-025-00976-x","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T20:25:45Z","timestamp":1764447945000},"page":"5-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["From Interaction to Intervention: Intentional CYP Inhibition as a Scalable Strategy to Expand Access to High-Cost Therapies"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0080-487X","authenticated-orcid":false,"given":"Fernando","family":"De la Garza Salazar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"976_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0338-x","volume":"10","author":"S Vincent Rajkumar","year":"2020","unstructured":"Vincent Rajkumar S. The high cost of prescription drugs: causes and solutions. Blood Cancer J. 2020;10:71. https:\/\/doi.org\/10.1038\/s41408-020-0338-x.","journal-title":"Blood Cancer J"},{"key":"976_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/GO.24.00043","author":"A Chan","year":"2024","unstructured":"Chan A, Ke Y, Tanay M, Dagsi M, Bergerot C, Dixit N, et al. Financial toxicity in cancer supportive care: an international survey. JCO Glob Oncol. 2024. https:\/\/doi.org\/10.1200\/GO.24.00043.","journal-title":"JCO Glob Oncol."},{"key":"976_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2024-015700","volume":"9","author":"M Li","year":"2024","unstructured":"Li M, Ka D, Chen Q. Disparities in availability of new cancer drugs worldwide: 1990\u20132022. BMJ Glob Health. 2024;9:e015700. https:\/\/doi.org\/10.1136\/bmjgh-2024-015700.","journal-title":"BMJ Glob Health"},{"key":"976_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00287-3","volume":"9","author":"A G\u00f3mez-De Le\u00f3n","year":"2022","unstructured":"G\u00f3mez-De Le\u00f3n A. The underrepresented majority. Lancet Haematol. 2022;9:e720. https:\/\/doi.org\/10.1016\/S2352-3026(22)00287-3.","journal-title":"Lancet Haematol"},{"key":"976_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40273-023-01320-4","volume":"42","author":"DT Michaeli","year":"2024","unstructured":"Michaeli DT, Michaeli T. Launch and post-launch prices of injectable cancer drugs in the US: clinical benefit, innovation, epidemiology, and competition. Pharmacoeconomics. 2024;42:117\u201331. https:\/\/doi.org\/10.1007\/s40273-023-01320-4.","journal-title":"Pharmacoeconomics"},{"key":"976_CR6","unstructured":"IQVIA Institute for Human Data Science. Global oncology trends 2024: Advancements and disparities in access to cancer care. [Internet]. IQVIA Institute for Human Data Science; 2024 [cited 2025 June 24]. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/global-oncology-trends-2024. Accessed June 24, 2025."},{"key":"976_CR7","doi-asserted-by":"publisher","unstructured":"Stacciarini JHS. The consolidation of the pharmaceutical sector in the global economy: growth, influence, deviations, and marketing [Internet]. SocArXiv; 2025 [cited 2025 June 24]. https:\/\/doi.org\/10.31235\/osf.io\/6728p_v1.","DOI":"10.31235\/osf.io\/6728p_v1"},{"key":"976_CR8","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/bcp.15590","volume":"89","author":"F De La Garza-Salazar","year":"2023","unstructured":"De La Garza-Salazar F, Colunga-Pedraza PR, G\u00f3mez-Almaguer D. Cytochrome P450 inhibition to decrease dosage and costs of venetoclax and ibrutinib: a proof-of-concept case study. Br J Clin Pharmacol. 2023;89:898\u2013902. https:\/\/doi.org\/10.1111\/bcp.15590.","journal-title":"Br J Clin Pharmacol"},{"key":"976_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/biom14010099","volume":"14","author":"J Lee","year":"2024","unstructured":"Lee J, Beers JL, Geffert RM, Jackson KD. A review of CYP-mediated drug interactions: mechanisms and in vitro drug-drug interaction assessment. Biomolecules. 2024;14:99. https:\/\/doi.org\/10.3390\/biom14010099.","journal-title":"Biomolecules"},{"key":"976_CR10","unstructured":"U.S. Food and Drug Administration. For healthcare professionals [Internet]. U.S. Food and Drug Administration; 2024 [cited 2025 June 14]. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems. Accessed June 14, 2025."},{"key":"976_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107373","volume":"133","author":"F De La Garza-Salazar","year":"2023","unstructured":"De La Garza-Salazar F, Colunga-Pedraza PR, G\u00f3mez-Almaguer D, Garc\u00eda-Z\u00e1rate VA, G\u00f3mez-De Le\u00f3n A. Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: a phase 2 study. Leuk Res. 2023;133:107373. https:\/\/doi.org\/10.1016\/j.leukres.2023.107373.","journal-title":"Leuk Res"},{"key":"976_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/bcp.15932","volume":"90","author":"AM Olkkola","year":"2024","unstructured":"Olkkola AM, Tapaninen T, Tornio A, Hauta-aho M, Lapatto-Reiniluoto O, Neuvonen M, et al. Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing: how to optimize ibrutinib dose during posaconazole treatment. Br J Clin Pharmacol. 2024;90:557\u201367. https:\/\/doi.org\/10.1111\/bcp.15932.","journal-title":"Br J Clin Pharmacol"},{"key":"976_CR13","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bcp.13175","volume":"83","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M, et al. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol. 2017;83:846\u201354. https:\/\/doi.org\/10.1111\/bcp.13175.","journal-title":"Br J Clin Pharmacol"},{"key":"976_CR14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1177\/0091270011405663","volume":"52","author":"JG Shi","year":"2012","unstructured":"Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharma. 2012;52:809\u201318. https:\/\/doi.org\/10.1177\/0091270011405663.","journal-title":"J Clin Pharma"},{"key":"976_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/cts.12716","volume":"13","author":"T Tapaninen","year":"2020","unstructured":"Tapaninen T, Olkkola AM, Tornio A, Neuvonen M, Elonen E, Neuvonen PJ, et al. Itraconazole increases ibrutinib exposure 10-fold and reduces interindividual variation\u2014a potentially beneficial drug-drug interaction. Clin Transl Sci. 2020;13:345\u201351. https:\/\/doi.org\/10.1111\/cts.12716.","journal-title":"Clin Transl Sci"},{"key":"976_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.6004\/jadpro.2023.14.5.7","volume":"14","author":"LK Lohr","year":"2023","unstructured":"Lohr LK, Blake KT, Chan CM, Sturm S, Walsh GT. Managing drug interactions with oral anticancer treatments. JADPRO. 2023;14:419\u201338. https:\/\/doi.org\/10.6004\/jadpro.2023.14.5.7.","journal-title":"JADPRO."},{"key":"976_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00280-020-04179-w","volume":"87","author":"S Bhatnagar","year":"2021","unstructured":"Bhatnagar S, Mukherjee D, Salem AH, Miles D, Menon RM, Gibbs JP. Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug\u2013drug interaction predictions using a PBPK approach. Cancer Chemother Pharmacol. 2021;87:465\u201374. https:\/\/doi.org\/10.1007\/s00280-020-04179-w.","journal-title":"Cancer Chemother Pharmacol"},{"key":"976_CR18","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/psp4.13146","volume":"13","author":"C Kovar","year":"2024","unstructured":"Kovar C, Loer HLH, R\u00fcdesheim S, Fuhr LM, Marok FZ, Selzer D, et al. A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug\u2013drug interactions. CPT Pharmacometr Syst Pharma. 2024;13:1144\u201359. https:\/\/doi.org\/10.1002\/psp4.13146.","journal-title":"CPT Pharmacometr Syst Pharma."},{"key":"976_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s11095-022-03244-8","volume":"39","author":"RJ Boosman","year":"2022","unstructured":"Boosman RJ, De Gooijer CJ, Groenland SL, Burgers JA, Baas P, Van Der Noort V, et al. Ritonavir-boosted exposure of kinase inhibitors: an open label, cross-over pharmacokinetic proof-of-concept trial with erlotinib. Pharm Res. 2022;39:669\u201376. https:\/\/doi.org\/10.1007\/s11095-022-03244-8.","journal-title":"Pharm Res"},{"key":"976_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer. N Engl J Med. 2018;378:113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"key":"976_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.21873\/anticanres.16211","volume":"43","author":"M Yamazaki","year":"2023","unstructured":"Yamazaki M, Komizo N, Iihara H, Hirose C, Yanase K, Yamada Y, et al. Relationship between osimertinib concentration and clinical response in Japanese patients with non-small cell lung cancer. Anticancer Res. 2023;43:725\u201332. https:\/\/doi.org\/10.21873\/anticanres.16211.","journal-title":"Anticancer Res"},{"key":"976_CR22","doi-asserted-by":"publisher","unstructured":"Westra N, Kruithof PD, Croes S, van Geel RMJM, Hendriks LEL, Touw DJ, et al. Osimertinib cost minimization in non-small cell lung cancer (NSCLC) treatment: hypothesis generation for a population pharmacokinetic approach for equivalent dose optimisation of osimertinib in combination with cobicistat. J Clin Pharmacol [Internet]. [cited 2025 Oct 8]. https:\/\/doi.org\/10.1002\/jcph.70085.","DOI":"10.1002\/jcph.70085"},{"key":"976_CR23","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1007\/s00277-024-05845-2","volume":"103","author":"M Hagihara","year":"2024","unstructured":"Hagihara M, Yasu T, Gando Y, Sugi T, Nakashima S, Imai Y, et al. Increased trough concentration of venetoclax when combined with itraconazole for acute myeloid leukemia. Ann Hematol. 2024;103:4497\u2013502. https:\/\/doi.org\/10.1007\/s00277-024-05845-2.","journal-title":"Ann Hematol"},{"key":"976_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041149","volume":"15","author":"N Westra","year":"2023","unstructured":"Westra N, Touw D, de Lub- Hooge M, Kosterink J, Oude Munnink T. Pharmacokinetic boosting of kinase inhibitors. Pharmaceutics. 2023;15:1149. https:\/\/doi.org\/10.3390\/pharmaceutics15041149.","journal-title":"Pharmaceutics"},{"key":"976_CR25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","volume":"9","author":"S Chen","year":"2023","unstructured":"Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9:465. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7826.","journal-title":"JAMA Oncol"},{"key":"976_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-90493-3","volume":"15","author":"YM Molla","year":"2025","unstructured":"Molla YM, Shad A, Wali R, Yimer MA. The magnitude and associated factors of childhood cancer treatment abandonment at the university of Gondar comprehensive specialized hospital, Ethiopia. Sci Rep. 2025;15:10534. https:\/\/doi.org\/10.1038\/s41598-025-90493-3.","journal-title":"Sci Rep"},{"key":"976_CR27","doi-asserted-by":"publisher","unstructured":"Marron JM, Charlot M, Gaddy J, Rosenberg AR. The ethical imperative of equity in oncology: lessons learned from 2020 and a path forward. Am Soc Clin Oncol Educ Book. 2021. https:\/\/doi.org\/10.1200\/EDBK_100029.","DOI":"10.1200\/EDBK_100029"},{"key":"976_CR28","doi-asserted-by":"publisher","unstructured":"Bamodu OA, Chung C-C. Cancer care disparities: overcoming barriers to cancer control in low- and middle-income countries. JCO Glob Oncol. 2024. https:\/\/doi.org\/10.1200\/GO.23.00439.","DOI":"10.1200\/GO.23.00439"},{"key":"976_CR29","doi-asserted-by":"publisher","first-page":"e1609","DOI":"10.1002\/onco.13822","volume":"26","author":"CM Nielson","year":"2021","unstructured":"Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis. Oncologist. 2021;26:e1609\u201318. https:\/\/doi.org\/10.1002\/onco.13822.","journal-title":"Oncologist"},{"key":"976_CR30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.5500\/wjt.v10.i11.356","volume":"10","author":"S M\u00e9ndez","year":"2020","unstructured":"M\u00e9ndez S, Ramay BM, Aguilar-Gonz\u00e1lez A, Lou-Meda R. Exploring the safety and efficacy of adding ketoconazole to tacrolimus in pediatric renal transplant immunosuppression. WJT. 2020;10:356\u201364. https:\/\/doi.org\/10.5500\/wjt.v10.i11.356.","journal-title":"WJT."},{"key":"976_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2025.05.008","author":"D Meng","year":"2025","unstructured":"Meng D, Li Y, Ruan M, Hou Z, Liu X, Wu W, et al. Safety and efficacy of grapefruit juice combined with low-dose venetoclax in AML patients ineligible for intensive chemotherapy. Clin Ther. 2025. https:\/\/doi.org\/10.1016\/j.clinthera.2025.05.008.","journal-title":"Clin Ther"},{"key":"976_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113346","volume":"194","author":"JK Overbeek","year":"2023","unstructured":"Overbeek JK, Guchelaar NAD, Mohmaed Ali MI, Ottevanger PB, Bloemendal HJ, Koolen SLW, et al. Pharmacokinetic boosting of olaparib: a randomised, cross-over study (PROACTIVE-study). Eur J Cancer. 2023;194:113346. https:\/\/doi.org\/10.1016\/j.ejca.2023.113346.","journal-title":"Eur J Cancer"},{"key":"976_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2025.101477","volume":"45","author":"JK Overbeek","year":"2025","unstructured":"Overbeek JK, Guchelaar NAD, Mohmaed Ali MI, Sark M, Hovenier C, Kievit W, et al. Pharmacokinetic boosting of olaparib: study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B). Contemp Clin Trials Commun. 2025;45:101477. https:\/\/doi.org\/10.1016\/j.conctc.2025.101477.","journal-title":"Contemp Clin Trials Commun"},{"key":"976_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/FTD.0000000000001288","volume":"47","author":"S Pattanaik","year":"2025","unstructured":"Pattanaik S, Monchaud C. Pharmacokinetic boosting of calcineurin inhibitors in transplantation: pros, cons, and perspectives. Ther Drug Monit. 2025;47:118\u201340. https:\/\/doi.org\/10.1097\/FTD.0000000000001288.","journal-title":"Ther Drug Monit"},{"key":"976_CR35","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1177\/1060028017717018","volume":"51","author":"A Tseng","year":"2017","unstructured":"Tseng A, Hughes CA, Wu J, Seet J, Phillips EJ. Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences. Ann Pharmacother. 2017;51:1008\u201322. https:\/\/doi.org\/10.1177\/1060028017717018.","journal-title":"Ann Pharmacother"},{"key":"976_CR36","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/bjh.18712","volume":"201","author":"F De la Garza-Salazar","year":"2023","unstructured":"De la Garza-Salazar F, Colunga-Pedraza PR, Coronado-Alejandro EU, Guti\u00e9rrez-Aguirre CH, Cant\u00fa-Rodr\u00edguez OG, G\u00f3mez-Almaguer D. Case series: CYP inhibition and low dose ibrutinib for steroid-refractory chronic graft-versus-host disease. Br J Haematol. 2023;201:573\u20136. https:\/\/doi.org\/10.1111\/bjh.18712.","journal-title":"Br J Haematol"},{"key":"976_CR37","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1111\/cts.13662","volume":"16","author":"E Hahn","year":"2023","unstructured":"Hahn E, Chavira R, Wollenberg L, Tan W, Reddy MB. Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations. Clin Transl Sci. 2023;16:2675\u201386. https:\/\/doi.org\/10.1111\/cts.13662.","journal-title":"Clin Transl Sci"},{"key":"976_CR38","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/jcph.109","volume":"53","author":"NI Narasimhan","year":"2013","unstructured":"Narasimhan NI, Dorer DJ, Niland K, Haluska F, Sonnichsen D. Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharma. 2013;53:974\u201381. https:\/\/doi.org\/10.1002\/jcph.109.","journal-title":"J Clin Pharma"},{"key":"976_CR39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00280-022-04466-8","volume":"90","author":"TO Morita","year":"2022","unstructured":"Morita TO, Hanada K. Physiologically based pharmacokinetic modeling of ponatinib to describe drug\u2013drug interactions in patients with cancer. Cancer Chemother Pharmacol. 2022;90:315\u201323. https:\/\/doi.org\/10.1007\/s00280-022-04466-8.","journal-title":"Cancer Chemother Pharmacol"},{"key":"976_CR40","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1002\/cam4.2269","volume":"8","author":"J Truong","year":"2019","unstructured":"Truong J, Chan KKW, Mai H, Chambers A, Sabharwal M, Trudeau ME, et al. The impact of pricing strategy on the costs of oral anti-cancer drugs. Cancer Med. 2019;8:3770\u201381. https:\/\/doi.org\/10.1002\/cam4.2269.","journal-title":"Cancer Med"},{"key":"976_CR41","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.2147\/RMHP.S418886","volume":"16","author":"J Li","year":"2023","unstructured":"Li J, He Y, Lei X, Cao Z, Liao Y, Wang G, et al. Combining the real-time vial sharing strategy with daily-rate charge mode for antimicrobial drugs of inpatients: an economical and practical method for patients and hospitals. Risk Manag Healthc Policy. 2023;16:1521\u201330. https:\/\/doi.org\/10.2147\/RMHP.S418886.","journal-title":"Risk Manag Healthc Policy"},{"key":"976_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.936686","author":"H Liu","year":"2022","unstructured":"Liu H, Zou L, Song Y, Yan J. Cost analysis of implementing a vial-sharing strategy for chemotherapy drugs using intelligent dispensing robots in a tertiary Chinese hospital in Sichuan. Front Public Health. 2022. https:\/\/doi.org\/10.3389\/fpubh.2022.936686.","journal-title":"Front Public Health"},{"key":"976_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11071013","volume":"11","author":"M Cozzio","year":"2023","unstructured":"Cozzio M, Melis A, La Fauci G, Guaraldi P, Caputo R, Lioi F, et al. Vial sharing of high-cost drugs to decrease leftovers and costs: a retrospective observational study on patisiran administration in Bologna, Italy. Healthcare. 2023;11:1013. https:\/\/doi.org\/10.3390\/healthcare11071013.","journal-title":"Healthcare"},{"key":"976_CR44","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3390\/biomedicines12030644","volume":"12","author":"M Kond\u017ea","year":"2024","unstructured":"Kond\u017ea M, Brizi\u0107 I, Joki\u0107 S. Flavonoids as CYP3A4 inhibitors in vitro. Biomedicines. 2024;12:644. https:\/\/doi.org\/10.3390\/biomedicines12030644.","journal-title":"Biomedicines"},{"key":"976_CR45","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/pharmaceutics13101715","volume":"13","author":"R Tabanelli","year":"2021","unstructured":"Tabanelli R, Brogi S, Calderone V. Improving curcumin bioavailability: current strategies and future perspectives. Pharmaceutics. 2021;13:1715. https:\/\/doi.org\/10.3390\/pharmaceutics13101715.","journal-title":"Pharmaceutics"},{"key":"976_CR46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s10020-023-00720-8","volume":"29","author":"H Tang","year":"2023","unstructured":"Tang H, Kuang Y, Wu W, Peng B, Fu Q. Quercetin inhibits the metabolism of arachidonic acid by inhibiting the activity of CYP3A4, thereby inhibiting the progression of breast cancer. Mol Med. 2023;29:127. https:\/\/doi.org\/10.1186\/s10020-023-00720-8.","journal-title":"Mol Med"},{"key":"976_CR47","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00280-019-03907-1","volume":"84","author":"V Aslanis","year":"2019","unstructured":"Aslanis V, Umehara K, Huth F, Ouatas T, Bharathy S, Butler AA, et al. Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects. Cancer Chemother Pharmacol. 2019;84:749\u201357. https:\/\/doi.org\/10.1007\/s00280-019-03907-1.","journal-title":"Cancer Chemother Pharmacol"},{"key":"976_CR48","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/10781552221110826","volume":"29","author":"F De La Garza-Salazar","year":"2023","unstructured":"De La Garza-Salazar F, Pe\u00f1a-Lozano SP, G\u00f3mez-Almaguer D, Colunga-Pedraza PR. Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor. J Oncol Pharm Pract. 2023;29:493\u20137. https:\/\/doi.org\/10.1177\/10781552221110826.","journal-title":"J Oncol Pharm Pract"},{"key":"976_CR49","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S0041-1345(03)00450-0","volume":"35","author":"L Soltero","year":"2003","unstructured":"Soltero L, Carbajal H, Rodr\u00edguez-Montalvo C, Vald\u00e9s A. Coadministration of tacrolimus and ketoconazole in renal transplant recipients: cost analysis and review of metabolic effects. Transplant Proc. 2003;35:1319\u201321. https:\/\/doi.org\/10.1016\/S0041-1345(03)00450-0.","journal-title":"Transplant Proc"},{"key":"976_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26707","author":"BA Jonas","year":"2022","unstructured":"Jonas BA, DiNardo C, Fracchiolla N, Pristupa A, Ishizawa K, Jin J, et al. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE\u2010A study. Am J Hematol. 2022. https:\/\/doi.org\/10.1002\/ajh.26707.","journal-title":"Am J Hematol"},{"key":"976_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1149298","volume":"13","author":"M Scium\u00e8","year":"2023","unstructured":"Scium\u00e8 M, Bosi A, Canzi M, Ceparano G, Serpenti F, De Roberto P, et al. Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia. Front Oncol. 2023;13:1149298. https:\/\/doi.org\/10.3389\/fonc.2023.1149298.","journal-title":"Front Oncol"},{"key":"976_CR52","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/bjh.19670","volume":"205","author":"B Weinbergerov\u00e1","year":"2024","unstructured":"Weinbergerov\u00e1 B, Mayer J, Kabut T, Sperr WR, \u0160tevkov\u00e1 J, Jon\u00e1\u0161ov\u00e1 A, et al. Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis. Br J Haematol. 2024;205:1746\u201350. https:\/\/doi.org\/10.1111\/bjh.19670.","journal-title":"Br J Haematol"},{"key":"976_CR53","doi-asserted-by":"publisher","first-page":"2433172","DOI":"10.1080\/16078454.2024.2433172","volume":"29","author":"X Zhong","year":"2024","unstructured":"Zhong X, Wang J, Dai Y, Huang X, Liu J, Xiang B, et al. Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia. Hematology. 2024;29:2433172. https:\/\/doi.org\/10.1080\/16078454.2024.2433172.","journal-title":"Hematology"},{"key":"976_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2025.14987","volume":"29","author":"S-Y Hsiao","year":"2025","unstructured":"Hsiao S-Y, Wu K-Y, Huang W-T, Lin C-Y, Chen K-Y, Weng T-S. Treatment outcomes and safety of reduced\u2011dose venetoclax plus antifungal agents to treat acute myeloid leukemia: a single hospital experience in Taiwan. Oncol Lett. 2025;29:1\u201310. https:\/\/doi.org\/10.3892\/ol.2025.14987.","journal-title":"Oncol Lett"},{"key":"976_CR55","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2519921","author":"RN Swain","year":"2025","unstructured":"Swain RN, Pattanaik S, Jain A, Wadhera S, Singh C, Khadwal A, et al. Comparable response rates of venetoclax 50 mg with posaconazole versus venetoclax 400 mg despite lower pharmacokinetic exposure in newly diagnosed acute myeloid leukemia: less is enough. Leuk Lymphoma. 2025. https:\/\/doi.org\/10.1080\/10428194.2025.2519921.","journal-title":"Leuk Lymphoma"},{"key":"976_CR56","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.3547","volume":"118","author":"NM Kyriacou","year":"2025","unstructured":"Kyriacou NM, Gross AS, McLachlan AJ. Green tea catechins as perpetrators of drug pharmacokinetic interactions. Clin Pharma Ther. 2025;118:45\u201361. https:\/\/doi.org\/10.1002\/cpt.3547.","journal-title":"Clin Pharma Ther."},{"key":"976_CR57","doi-asserted-by":"publisher","DOI":"10.7324\/JAPS.2024.160197","author":"WA Dayyih","year":"2024","unstructured":"Dayyih WA, Ani IA, Hailat M, Alarman SM, Zakaraya Z, Assab MA, et al. Review of grapefruit juice-drugs interactions mediated by intestinal CYP3A4 inhibition. J Appl Pharm Sci. 2024. https:\/\/doi.org\/10.7324\/JAPS.2024.160197.","journal-title":"J Appl Pharm Sci."},{"key":"976_CR58","unstructured":"U.S. Food and Drug Administration. Grapefruit juice and some drugs don\u2019t mix. [Internet]. U.S. Food and Drug Administration; 2024 [cited 2025 June 14]. https:\/\/www.fda.gov\/consumers\/consumer-updates\/grapefruit-juice-and-some-drugs-dont-mix. Accessed June 14, 2025."},{"key":"976_CR59","doi-asserted-by":"publisher","first-page":"1358956","DOI":"10.3389\/fmedt.2024.1358956","volume":"6","author":"AR Gatt","year":"2024","unstructured":"Gatt AR, Vella Bonanno P, Zammit R. Ethical considerations in the regulation and use of herbal medicines in the European Union. Front Med Technol. 2024;6:1358956. https:\/\/doi.org\/10.3389\/fmedt.2024.1358956.","journal-title":"Front Med Technol."},{"key":"976_CR60","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(21)00463-0","volume":"22","author":"A Fundytus","year":"2021","unstructured":"Fundytus A, Sengar M, Lombe D, Hopman W, Jalink M, Gyawali B, et al. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol. 2021;22:1367\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(21)00463-0.","journal-title":"Lancet Oncol"},{"key":"976_CR61","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2217\/pgs-2022-0123","volume":"23","author":"X Cheng","year":"2022","unstructured":"Cheng X, Chen Y, Zhang L, Chen B, Yang D, Chen W, et al. Influence of CYP3A5, IL-10 polymorphisms and metabolism rate on tacrolimus exposure in renal post-transplant recipients. Pharmacogenomics. 2022;23:961\u201372. https:\/\/doi.org\/10.2217\/pgs-2022-0123.","journal-title":"Pharmacogenomics"},{"key":"976_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","volume":"18","author":"RJ Kathawala","year":"2015","unstructured":"Kathawala RJ, Gupta P, Ashby CR, Chen Z-S. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updates. 2015;18:1\u201317. https:\/\/doi.org\/10.1016\/j.drup.2014.11.002.","journal-title":"Drug Resist Updates"},{"key":"976_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ddc4020024","volume":"4","author":"M Kond\u017ea","year":"2025","unstructured":"Kond\u017ea M, Buki\u0107 J, \u0106avar I, Tubi\u0107 B. Targeted but troubling: CYP450 inhibition by kinase and PARP inhibitors and its clinical implications. Drugs Drug Candidates. 2025;4:24. https:\/\/doi.org\/10.3390\/ddc4020024.","journal-title":"Drugs Drug Candidates"},{"key":"976_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116383","volume":"309","author":"A Choudhury","year":"2023","unstructured":"Choudhury A, Singh PA, Bajwa N, Dash S, Bisht P. Pharmacovigilance of herbal medicines: concerns and future prospects. J Ethnopharmacol. 2023;309:116383. https:\/\/doi.org\/10.1016\/j.jep.2023.116383.","journal-title":"J Ethnopharmacol"},{"key":"976_CR65","doi-asserted-by":"publisher","DOI":"10.2196\/63808","volume":"10","author":"C Kongkaew","year":"2024","unstructured":"Kongkaew C, Phan DTA, Janusorn P, Mongkhon P. Estimating adverse events associated with herbal medicines using pharmacovigilance databases: systematic review and meta-analysis. JMIR Public Health Surveill. 2024;10:e63808. https:\/\/doi.org\/10.2196\/63808.","journal-title":"JMIR Public Health Surveill"},{"key":"976_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.628744","volume":"9","author":"P Ocran Mattila","year":"2021","unstructured":"Ocran Mattila P, Ahmad R, Hasan SS, Babar Z-U-D. Availability, affordability, access, and pricing of anti-cancer medicines in low- and middle-income countries: a systematic review of literature. Front Public Health. 2021;9:628744. https:\/\/doi.org\/10.3389\/fpubh.2021.628744.","journal-title":"Front Public Health"},{"key":"976_CR67","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s44247-025-00153-9","volume":"3","author":"L Ph","year":"2025","unstructured":"Ph L, Mt M, Plgc L. Effectiveness of mobile applications in enhancing adverse drug reaction reporting: a systematic review. BMC Digit Health. 2025;3:15. https:\/\/doi.org\/10.1186\/s44247-025-00153-9.","journal-title":"BMC Digit Health"},{"key":"976_CR68","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.annonc.2022.06.010","volume":"33","author":"SL Groenland","year":"2022","unstructured":"Groenland SL, Van Eerden RAG, Westerdijk K, Meertens M, Koolen SLW, Moes DJAR, et al. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study. Ann Oncol. 2022;33:1071\u201382. https:\/\/doi.org\/10.1016\/j.annonc.2022.06.010.","journal-title":"Ann Oncol"},{"key":"976_CR69","unstructured":"U.S. Food and Drug Administration. Clinical drug interaction studies\u2014cytochrome P450 enzyme- and transporter-mediated drug interactions: guidance for industry [Internet]. U.S. Food and Drug Administration; 2020 [cited 2025 June 24]. https:\/\/collections.awsprod.nlm.nih.gov\/catalog\/nlm:nlmuid-101767654-pdf. Accessed June 24, 2025."},{"key":"976_CR70","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions [Internet]. European Medicines Agency; 2012 [cited 2025 June 24]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf. Accessed June 24, 2025."},{"key":"976_CR71","unstructured":"U.S. Food and Drug Administration. Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers [Internet]. U.S. Food and Drug Administration; 2023 [cited 2025 June 14]. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers?. Accessed June 14, 2025."},{"key":"976_CR72","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001056","author":"CJ Beavers","year":"2022","unstructured":"Beavers CJ, Rodgers JE, Bagnola AJ, Beckie TM, Campia U, Di Palo KE, et al. Cardio-oncology drug interactions: a scientific statement from the American Heart Association. Circulation. 2022. https:\/\/doi.org\/10.1161\/CIR.0000000000001056.","journal-title":"Circulation"},{"key":"976_CR73","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s13318-024-00915-2","volume":"49","author":"T Hirai","year":"2024","unstructured":"Hirai T, Aoyama T, Tsuji Y, Ino K, Ikejiri M, Tawara I, et al. Pharmacokinetic model of drug interaction of tacrolimus with combined administration of CYP3A4 inhibitors voriconazole and clarithromycin after bone marrow transplantation. Eur J Drug Metab Pharmacokinet. 2024;49:763\u201371. https:\/\/doi.org\/10.1007\/s13318-024-00915-2.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"976_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2023-013583","volume":"8","author":"MCS Ishimwe","year":"2023","unstructured":"Ishimwe MCS, Kiplagat J, Kadam Knowlton A, Livinski AA, Kupfer LE. Reversing the trend: a scoping review of health innovation transfer or exchange from low- and middle-income countries to high-income countries. BMJ Glob Health. 2023;8:e013583. https:\/\/doi.org\/10.1136\/bmjgh-2023-013583.","journal-title":"BMJ Glob Health"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00976-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00976-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00976-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:38:48Z","timestamp":1771861128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00976-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["976"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00976-x","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No ethics approval was required as this manuscript does not involve new patient data collection or experimental procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}